Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria
about
Maintenance chemotherapy for ovarian cancerMaintenance bioimmunotherapy for epithelial ovarian cancerMaintenance chemotherapy for ovarian cancerTumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancerResidual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.Chemotherapy of ovarian cancer in elderly patientsAn Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic ReviewHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerMaintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old ideaPerioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial CarcinomaAdvanced ovarian cancer: what should be the standard of care?The promise and perils of 'targeted therapy' of advanced ovarian cancerChemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesA phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma.Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma.Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin.Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance.Current status of maintenance therapy for advanced ovarian cancer.Clinical trials and progress with paclitaxel in ovarian cancerClinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinomaPrognosis and conditional disease-free survival among patients with ovarian cancerRisk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels.Immunization with synthetic VEGF peptides in ovarian cancerA randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group StudyPractical considerations in ovarian cancer chemotherapy.Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancerConsolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer.First-line therapy for ovarian carcinoma: what's next?Novel agents in epithelial ovarian cancer.The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.Monoclonal antibody therapy of ovarian cancer.Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validationSystemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approachesEmerging drugs for ovarian cancer.Treatment options in the management of ovarian cancer.
P2860
Q24201758-8BC682F9-2B97-4F08-9F06-33E4D673C7FFQ24234761-E4133CE6-EAA6-42BA-8FFC-122DF7AA8D6EQ24235427-1A91C9C7-ACEA-44AE-B128-AA34F620B2DAQ24650026-6E5D628B-9AEB-408B-9DB9-A5B6D9259E1BQ25257587-9390DDB3-F2C7-4671-A9F5-F6D07FDE0F19Q26771397-10FFA677-0513-43E3-B62F-F9AE70424713Q26777085-0DBAE644-E718-454D-A01C-9EF77D980C13Q26783551-F962A8AF-9D81-4B3A-AF48-0792BA1F5BDCQ27011282-C1B75957-B91F-472D-AF8F-15E815EA2BB7Q27024948-4E821378-FD3E-4856-A06F-F414CBA07C65Q27852053-1FF9D312-279B-4289-A7A8-71B8B0D5794AQ28282889-7242B0F8-5226-43D6-B5EE-A83712D8FD33Q33314684-45E162CD-7FBD-4D3E-9826-D6CA0127AE90Q33315604-61DA6009-F65B-4AAE-B112-B2E4F08CA6F2Q33407574-BAF7EE45-1140-46A7-8F2F-79C70459853CQ33419382-7C55E3EF-0A89-4353-8BC2-3E1995EB0844Q33419612-9D4B76FD-C981-4ED6-A4A8-9B3A176117EBQ33705325-03967289-3289-4F1C-B50C-4402C440C5DDQ34011165-E97A9B2F-79C1-4CFE-9459-9BE86A7398DEQ34271924-FCCF4A94-EE1C-4FC7-A7D3-CC769C0BB70DQ34510070-3876ECA2-50B9-4886-AEBB-77C6E3317565Q34626854-FB6C7287-FF1D-4E6B-A00B-6A0D6A52D903Q34692286-FA75E791-CBB6-4B33-8239-ACACBCD886CFQ34838655-E70F192E-B3F3-42A2-8431-B9836FE5D415Q34901858-61F3D13C-C1EF-4CE3-9E66-BF28EC44D506Q35033234-B12FEDFF-1B29-42FF-B31F-1624E270B932Q35076260-C6455067-E4B0-4F0E-8596-4649F4D5BC6EQ35114915-76454EBB-0BE4-4675-A921-54478822B12CQ35154140-447089E1-CDD5-4F8B-8DFF-45103CB6BCBDQ35564007-9F25584B-0747-4537-A076-F4EB6B7C408CQ35842690-94305BC0-8779-47E2-A601-4C1D64E507EDQ35968742-88CC9183-FA43-4FD8-86F9-0BB76BFF51C8Q35968748-B6689626-8DA4-4ECC-B65F-284DA0EC860DQ35968752-3AA896C7-B595-429E-8853-360C39C45575Q36063233-FD4330CC-A917-414E-B715-AD47A6BB1CC9Q36066157-B253375E-059B-495F-88CB-EC2D6ACBF4B7Q36076716-414CF802-2334-45ED-9660-85A1534EF73DQ36144210-53422A13-5A5C-4C06-987E-54875FACDDAEQ36150652-597F82AF-5F72-4A67-821C-5FAFE38C9270Q36150781-2C7B127B-C416-4FEB-B1D1-5468CE704405
P2860
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Phase III randomized trial of ...... ynecologic Oncology Group tria
@en
Phase III randomized trial of ...... ynecologic Oncology Group tria
@nl
type
label
Phase III randomized trial of ...... ynecologic Oncology Group tria
@en
Phase III randomized trial of ...... ynecologic Oncology Group tria
@nl
prefLabel
Phase III randomized trial of ...... ynecologic Oncology Group tria
@en
Phase III randomized trial of ...... ynecologic Oncology Group tria
@nl
P2093
P921
P356
P1476
Phase III randomized trial of ...... ynecologic Oncology Group tria
@en
P2093
Bradley Monk
Caroline Jiang
David Alberts
Gynecologic Oncology Group
Larry J Copeland
Maurie Markman
Ronald D Alvarez
Sharon Wilczynski
P304
P356
10.1200/JCO.2003.07.013
P407
P50
P577
2003-07-01T00:00:00Z